Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

29-09-2019 | Non-small-cell lung cancer | Video | Article

Researcher comment: Positive OS data for osimertinib in FLAURA trial

print
PRINT
insite
SEARCH

Suresh Ramalingam presents the overall survival analysis of the FLAURA trial of osimertinib in EGFR mutation-positive, advanced non-small-cell lung cancer, and discusses the options after progression on the tyrosine kinase inhibitor (1:50).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read the transcript

print
PRINT

Related content

29-09-2019 | Non-small-cell lung cancer | Conference coverage | News

FLAURA shows OS boost with osimertinib in advanced NSCLC

02-10-2019 | Non-small-cell lung cancer | Video | Article

Expert highlights: Lung and thoracic cancers at ESMO 2019

03-04-2019 | Non-small-cell lung cancer | Conference coverage | News

Osimertinib combinations promising for NSCLC patients with acquired resistance to EGFR–TKIs

21-10-2018 | Non-small-cell lung cancer | ESMO 2018 | News

Candidate mutations underlying acquired resistance to osimertinib mapped
Image Credits